| Budget Amount *help |
¥27,820,000 (Direct Cost: ¥21,400,000、Indirect Cost: ¥6,420,000)
Fiscal Year 2013: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
Fiscal Year 2012: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
Fiscal Year 2011: ¥14,560,000 (Direct Cost: ¥11,200,000、Indirect Cost: ¥3,360,000)
|
|---|
| Research Abstract |
Many pathogenic bacteria, including Shigella, enteropathogenic Escherichia coli (EPEC), and enterohemorrhagic E.coli (EHEC), are associated with diarrheal diseases in young children in developing countries. Although these pathogens are a significant health threat in the developing world, many Japanese people have suffered from O157 infection. However, no effective vaccines have yet been developed. Multi-drug resistant bacteria are increasing problem. Therefore, we aim to develop new therapeutic tools to counteract the progression of these diseases.
To develop therapeutic tools against Shigella infection, we have analyzed the role of OspE during Shigella infection. ospE family genes are highly conserved among many enteropathogenic bacteria, including Shigella, O157, Citrobacter rodentium, and Salmonella, suggesting that OspE plays a general role in bacterial infection. We show here that OspE homologs play a key role in the establishment of during other pathogenic bacteria infection.
|
